• Home
    Chevron
  • Resources
    Chevron
  • FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency

FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency

Subjects: Education, Clinical, Research Type: Technical Assistance, Tools, Reports, Manuals, Implementation Guides, Definitions Tags: Covid 19, Opioid Use Disorder, Opioid, Substance Use Disorder, Buprenorphine, Medication Assisted Treatment, Telehealth, Government, SAMHSA, Pain Management, Recovery, SBIRT, Screening, Prevention, Treatment Guidelines, Workflow, Tip Sheet

Patients with a substance use disorder (SUD), mental illness or chronic pain are among those who may be acutely affected by interruptions in medical care, including interruptions in access to medications used as part of their treatment regimen.

As the COVID-19 pandemic continues to challenge our health care system, the SAMHSA encourages providers to use the FAQ information below as guidance to help ensure continuity of care for their patients.